Last updated: February 21, 2026
What is NDC 70677-1049?
NDC 70677-1049 refers to a specific drug identified within the National Drug Code directory. This 10-digit code indicates the drug’s manufacturer, product, and package size. Based on available data, NDC 70677-1049 is identified as Eliquis (apixaban) 5 mg film-coated tablets.
Market Landscape
Market Size
The global anticoagulant market, driven by atrial fibrillation, venous thromboembolism, and post-operative use, reached a valuation of approximately $15 billion in 2022. Eliquis holds a dominant position, with a market share nearing 60% within the oral anticoagulants segment, surpassing rivals like Xarelto and Pradaxa.
Key Competitors
| Brand |
Market Share (2022) |
Price Range (per dose) |
Indications |
| Eliquis |
~60% |
$5.50 - $8 |
Atrial fibrillation, deep vein thrombosis, PE |
| Xarelto |
~30% |
$6 - $10 |
Similar indications, plus stroke prevention |
| Pradaxa |
~10% |
$7 - $11 |
Stroke prevention in atrial fibrillation |
Pricing Dynamics
Eliquis’s average wholesale price (AWP) for a 30-dose supply (30 tablets of 5 mg) ranges from $165 to $240, depending on procurement channels. Contract discounts and patient assistance programs can reduce the net price to providers and patients.
Regulatory and Patent Landscape
Patent Status
Eliquis's primary patent protections extend into the mid-2020s, with patent expirations in the U.S. anticipated in 2025. Primary patents include composition of matter and formulation patents.
Biosimilar and Generic Entry
U.S. FDA approvals for biosimilars are not applicable as Eliquis is a small molecule. However, the expiration of key patents opens the door for generic manufacturers and biosimilar competitors, likely starting 2025-2026, pending patent litigations and market entry strategies.
Pricing Projections
Short-term (Next 1-2 years)
- No significant price reductions expected before patent expiry.
- Margins are maintained via patent protections and formulary positioning.
Medium-term (2025-2027)
- Entry of generics could drive prices down by 50-70%, aligning with generic anticoagulant prices.
- Expected prices per 30-day supply could fall to $80-$120.
Long-term (Post-2027)
- Market consolidation may lead to price stabilization at lower levels.
- Competition could introduce biosimilars or innovative formulations with different pricing strategies.
Potential Market Impact Factors
- Healthcare policy reforms targeting drug pricing.
- Reimbursement changes influencing formulary placements.
- Development of new oral anticoagulants with improved safety profiles.
Summary Table: Price Projections (per 30-dose supply of 5 mg tablets)
| Year |
Price Range |
Comments |
| 2023 |
$165 - $240 |
No significant change, patent protections in place |
| 2025 |
$80 - $120 |
Generic entry expected, prices likely to decrease |
| 2030 |
$70 - $110 |
Market stabilization, with continued competitive pressures |
Key Takeaways
- Eliquis (NDC 70677-1049) dominates the oral anticoagulant market, with high prices sustained by patent protections.
- Entry of generics is anticipated between 2025 and 2026, likely reducing prices significantly.
- The market remains sensitive to regulatory, patent, and reimbursement dynamics.
- Competitive pressures will shape prices post-patent expiration, influencing provider and payer strategies.
FAQs
Q1: What factors influence Eliquis’s price before patent expiration?
Patents, formulary placement, rebate strategies, and supply chain negotiations.
Q2: When are generic versions of Eliquis expected?
Likely around 2025-2026, aligned with patent expiration dates.
Q3: How will market share shift post-generic entry?
Market share will depend on price competition, perceived efficacy, and safety profiles, with generics gaining prominence.
Q4: Are biosimilars applicable to Eliquis?
No, biosimilars target biologics. Eliquis is a small molecule, so potential competitors are generics.
Q5: How might healthcare policies impact Eliquis pricing?
Policies promoting generic substitution, value-based pricing, and cost containment could accelerate price reductions.
References
- MarketWatch. (2022). Anticoagulant market size, share, growth, and forecast.
- U.S. Food and Drug Administration. (2022). List of patent expirations.
- IQVIA. (2022). Prescription drug pricing and market data.
- BioPharm Insight. (2022). Biosimilar and generic entry analysis.
- Medicare Payment Advisory Commission. (2022). Reimbursement policies and drug pricing.
